WNYUZ
No Result
View All Result
  • Home
  • Politics
  • Opinion
  • Business
  • World
  • Health
  • Entertainment
  • Tech
  • Home
  • Politics
  • Opinion
  • Business
  • World
  • Health
  • Entertainment
  • Tech
No Result
View All Result
WNYUZ
No Result
View All Result
Home News

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs

June 7, 2025
in News
Yahoo news home
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

By Sneha S K and Sriparna Roy

(Reuters) -Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would look for ways to fast-track approval for rare disease treatments and remove obstacles to their path to market.

Kennedy made the comments at a U.S. Food and Drug Administration meeting to discuss cell and gene therapies, where panelists called for faster regulatory processes as they warned that other countries may overtake the U.S. in drug development.

“We are going to continue to figure out new ways of accelerating approvals for drugs and treatments that treat rare diseases, and we’re going to make this country the hub of biotechnology innovation,” Kennedy said.

Other members included industry executives, researchers and FDA staffers, among them Vinay Prasad, the FDA’s top vaccine and biologics official.

The appointment of Prasad as the head of the FDA’s Center for Biologics Evaluation and Research had stoked fears that he could raise the bar for companies to get approval for new drugs, including what are known as accelerated approvals for new potential treatments of serious conditions.

Prasad vowed at the meeting to rapidly make therapies available at the first sign or promise of biomedical success or action.

Shares of therapy developers Sarepta, Dyne Therapeutics and Lexeo Therapeutics were trading between 1% and 3% higher in afternoon trading. U.S.-listed shares of uniQure rose 8.19% to $16.18.

Panel members said that the slower regulatory process for rare disease treatments risks the United States’ position as a leader in the biotechnology sector at a time when drug development in China is accelerating.

“The path to approval is seen as so arduous. If firms feel there is no credible way to get new products approved here, they will simply relocate trials overseas or abandon them,” panel member Carl June from University of Pennsylvania.

“We cannot afford that exodus,” said June.

(Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing by Alan Barona)

The post US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs appeared first on Reuters.

Tags: drug developmentHealth and Human ServicesKennedyrare diseaseregulatory processesReutersRobert F. Kennedy Jr.Vinay PrasadYahooYahoo News
Share196Tweet123Share
Yahoo news home
News

House Ethics report finds AOC ‘impermissibly accepted gifts’ related to 2021 Met Gala appearance

July 26, 2025

The House Ethics Committee found that Democratic Rep. Alexandria Ocasio-Cortez “impermissibly accepted gifts” in connection with her 2021 appearance at ...

Read more
News

To former prosecutors, DOJ interview with Ghislaine Maxwell looked unorthodox

July 26, 2025
News

Maxwell’s lawyer says she’s undecided on appearing for congressional testimony

July 25, 2025
News

The good, the bad, and the just plain weird

July 25, 2025
News

Lori Vallow Daybell receives life in prison for 2 Arizona murder conspiracy convictions

July 25, 2025
US Criticizes Macron for Opting to Recognize Palestinian State

US Criticizes Macron for Opting to Recognize Palestinian State

July 25, 2025
Yahoo entertainment home

‘South Park’s Trey Parker Deadpans At Comic-Con In Response To Donald Trump’s Reaction To Season 27 Premiere: “We’re Terribly Sorry”

July 25, 2025
Yahoo news home

Trump says he hasn’t considered pardoning Epstein associate Ghislaine Maxwell

July 25, 2025

© 2025 WNyuz.com

No Result
View All Result
  • Home
  • Politics
  • Opinion
  • Business
  • World
  • Health
  • Entertainment
  • Tech

© 2025 WNyuz.com